Development of AhR inhibitors for oral antiviral therapy for COVID-19 patients (Q3988868): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the infer coords bot - inferring coordiantes from postal codes) |
(Changed label, description and/or aliases in en: Adding English translations) |
||
label / en | label / en | ||
Development of AhR inhibitors for oral antiviral therapy for COVID-19 patients |
Revision as of 19:48, 13 December 2021
Project Q3988868 in Netherlands
Language | Label | Description | Also known as |
---|---|---|---|
English | Development of AhR inhibitors for oral antiviral therapy for COVID-19 patients |
Project Q3988868 in Netherlands |
Statements
399,362.0 Euro
0 references
1,055,117.569 Euro
0 references
37.85 percent
0 references
1 June 2020
0 references
1 June 2021
0 references
Hercules Pharmaceuticals
0 references
2333BD
0 references
9747AT
0 references
Identifiers
OP-2014-2023-Noord-OPSNN0302
0 references